



01.22.24

## An Open Letter to the Organ Transplant Community

The U.S. organ transplant community stands at a consequential inflection point with the Health Resources and Services Administration (HRSA)'s Modernization Initiative, following the recent unanimous bipartisan support for the "Securing the U.S. Organ Procurement and Transplantation Network (OPTN) Act."

As a patient-founded and patient-centric 501(c)(3) nonprofit designed to radically improve organ transplant outcomes through data, we at Valeos celebrate the interest in advancing today's system through both incremental advancement and bold transformation. We also recognize that the success—or failure—of these changes is measured in human lives and relies on flawless implementation.

We're writing this letter to share that **Valeos will not submit a response proposal for the upcoming OPTN contract solicitations**. We believe our ability to advance outcomes for transplant patients and donors is better served independent of HRSA's approach outlined in its December 2023 Updates.

Our perspective on HRSA's modernization plans has been shared publicly and privately, including through our 2022 OPTN RFI response, as guests of multiple OPTN Industry Day events, and in private meetings with HRSA. We've consistently highlighted two topics which we view as critical to this initiative that we still believe need improvement:

- Longitudinal clinical and outcomes data must be a foundational element of the OPTN to guide decision-making and improve the ecosystem's performance.
- A restructured OPTN Board of Directors must adhere to principles of effective board governance with reasonable board size, independence, and a member composition that represents key functional disciplines for its purpose.

We will continue to share our perspective with HRSA, engage with the OPTN Board of Directors, and look forward to collaborating with selected OPTN vendors.

Valeos remains committed to striving for an optimal transplant system with greater access to more high-quality transplants, reduced waitlist times, and improved post-transplant results.

Onwards,  
Valeos